Kenneth A. Lock
Net Worth
Last updated:
What is Kenneth A. Lock net worth?
The estimated net worth of Mr. Kenneth A. Lock is at least $3,643,683 as of 6 Mar 2023. He owns shares worth $987,970 as insider, has earned $84,313 from insider trading and has received compensation worth at least $2,571,400 in Arcutis Biotherapeutics, Inc..
What is the salary of Kenneth A. Lock?
Mr. Kenneth A. Lock salary is $514,280 per year as Chief Commercial Officer in Arcutis Biotherapeutics, Inc..
How old is Kenneth A. Lock?
Mr. Kenneth A. Lock is 51 years old, born in 1974.
What stocks does Kenneth A. Lock currently own?
As insider, Mr. Kenneth A. Lock owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | Chief Commercial Officer | 63,429 | $15.58 | $987,970 |
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Kenneth A. Lock insider trading
Arcutis Biotherapeutics, Inc.
Mr. Kenneth A. Lock has made 8 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 831 units of ARQT stock worth $12,684 on 6 Mar 2023.
The largest trade he's ever made was exercising 7,500 units of ARQT stock on 15 Oct 2020. As of 6 Mar 2023 he still owns at least 63,429 units of ARQT stock.
Arcutis Biotherapeutics key executives
Arcutis Biotherapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Bhaskar Chaudhuri Ph.D. (70) Co-Founder & Independent Director
- Dr. Patrick E. Burnett M.D., Ph.D. (53) Senior Vice President & Chief Medical Officer
- Mr. Kenneth A. Lock (51) Chief Commercial Officer
- Mr. Todd Franklin Watanabe (57) Pres, Chief Executive Officer & Director